Related references
Note: Only part of the references are listed.Metformin: A Potential Therapeutic Agent for Recurrent Colon Cancer
Pratima Nangia-Makker et al.
PLOS ONE (2014)
Metformin Induces Apoptosis and Cell Cycle Arrest Mediated by Oxidative Stress, AMPK and FOXO3a in MCF-7 Breast Cancer Cells
Eveline A. I. F. Queiroz et al.
PLOS ONE (2014)
Effects of Metformin on CD133+Colorectal Cancer Cells in Diabetic Patients
Yanfei Zhang et al.
PLOS ONE (2013)
Metformin inhibits inflammatory response via AMPK-PTEN pathway in vascular smooth muscle cells
Sun Ae Kim et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
Diabetes, metformin use, and colon cancer: a population-based cohort study in Taiwan
Chin-Hsiao Tseng
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2012)
Reduced Risk of Colorectal Cancer With Metformin Therapy in Patients With Type 2 Diabetes A meta-analysis
Zhi-Jiang Zhang et al.
DIABETES CARE (2011)
Cytokine Induction of Tumor Necrosis Factor Receptor 2 Is Mediated by STAT3 in Colon Cancer Cells
Kathryn E. Hamilton et al.
MOLECULAR CANCER RESEARCH (2011)
Metformin blocks migration and invasion of tumour cells by inhibition of matrix metalloproteinase-9 activation through a calcium and protein kinase Cα-dependent pathway: phorbol-12-myristate-13-acetate-induced/extracellular signal-regulated kinase/activator protein-1
Yong P. Hwang et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Roles for Inflammation and Regulatory T Cells in Colon Cancer
Susan E. Erdman et al.
TOXICOLOGIC PATHOLOGY (2010)
Inflammation and Cancer: IL-6 and STAT3 Complete the Link
Jacqueline Bromberg et al.
CANCER CELL (2009)
Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability
Francesco Colotta et al.
CARCINOGENESIS (2009)
Inhibition of cell proliferation and invasion in a human colon cancer cell line by 5-aminosalicylic acid
Y. -H. Kim et al.
DIGESTIVE AND LIVER DISEASE (2009)
Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis
Sunhwa Kim et al.
NATURE (2009)
Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid
Carmine Stolfi et al.
BIOCHEMICAL PHARMACOLOGY (2008)
Effects of COX-2 inhibition on expression of vascular endothelial growth factor and interleukin-8 in lung cancer cells
Yong Ming Zhu et al.
BMC CANCER (2008)
Glycosylated Hemoglobin and Risk of Colorectal Cancer in Men and Women, the European Prospective Investigation into Cancer and Nutrition
Sabina Rinaldi et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2008)
NF-κB and cancer -: identifying targets and mechanisms
Willscott E. Naugler et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2008)
5-Aminosalicylic Acid Inhibits Colitis-Associated Colorectal Dysplasias in the Mouse Model of Azoxymethane/Dextran Sulfate Sodium-Induced Colitis
Margie L. Clapper et al.
INFLAMMATORY BOWEL DISEASES (2008)
5-aminosalicylic acid given in the remission stage of colitis suppresses colitis-associated cancer in a mouse colitis model
Ikuko Ikeda et al.
CLINICAL CANCER RESEARCH (2007)
Expression of epidermal growth factor receptor (EGFR) is frequent in inflammatory bowel disease (IBD)-associated intestinal cancer
Magali Svrcek et al.
VIRCHOWS ARCHIV (2007)
Interleukin-1β-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors
Yakov Krelin et al.
CANCER RESEARCH (2007)
Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/β-catenin pathway activity
Carina L. Bos et al.
CARCINOGENESIS (2006)
Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis
David T. Rubin et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
5-aminosalicylic acid enhances anchorage-independent colorectal cancer cell death
Daniele Fina et al.
EUROPEAN JOURNAL OF CANCER (2006)
Nuclear factor-κB in cancer development and progression
Michael Karin
NATURE (2006)
Silencing of SH-PTP2 defines a crucial role in the inactivation of epidermal growth factor receptor by 5-aminosalicylic acid in colon cancer cells
G Monteleone et al.
CELL DEATH AND DIFFERENTIATION (2006)
Diabetes mellitus and risk of colorectal cancer: A meta-analysis
SC Larsson et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth
FM Corvinus et al.
NEOPLASIA (2005)
Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-γ
C Rousseaux et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Impact of EGFR expression on colorectal cancer patient prognosis and survival
JP Spano et al.
ANNALS OF ONCOLOGY (2005)
Review article: colorectal carcinoma and inflammatory bowel disease
J Eaden
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
The IKKNF-kappa B system: A treasure trove for drug development
M Karin et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Review article: the data supporting a role for aminosalicylates in the chemoprevention of colorectal cancer in patients with inflammatory bowel disease
J Eaden
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)
The immunological and genetic basis of inflammatory bowel disease
G Bouma et al.
NATURE REVIEWS IMMUNOLOGY (2003)
Tumor necrosis factor regulates intestinal epithelial cell migration by receptor-dependent mechanisms
J Corredor et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2003)
Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells
A Reinacher-Schick et al.
CARCINOGENESIS (2003)
Fasting insulin and outcome in early-stage breast cancer: Results of a prospective cohort study
PJ Goodwin et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared
JM Rhodes et al.
TRENDS IN MOLECULAR MEDICINE (2002)
Interleukin-1 polymorphisms associated with increased risk of gastric cancer
EM El-Omar et al.
NATURE (2000)
Inhibitory effect of metformin on intestinal glucose absorption in the perfused rat intestine
T Ikeda et al.
BIOCHEMICAL PHARMACOLOGY (2000)
The distinct roles of TRAF2 and RIP in IKK activation by TNF-R1: TRAF2 recruits IKK to TNF-R1 while RIP mediates IKK activation
A Devin et al.
IMMUNITY (2000)
Share Paper
